Company profile: H&T Presspart
1.1 - Company Overview
Company description
- Provider of drug delivery devices and manufacturing services for asthma and COPD, offering metered-dose inhalation devices and components (actuators, dose counters), dry powder inhalers including PowdAir Plus, comprehensive drug delivery device development from design to manufacturing, high-precision injection moulding, automated multi-component assembly, and deep drawing of metal components such as MDI cans.
Products and services
- Deep Drawing: Precision manufacturing produces metal components for pharmaceutical applications, including MDI cans for metered-dose inhalers
- Dry Powder Inhalation: Powder-form inhalers deliver medication for conditions such as asthma and COPD, including the PowdAir Plus device for dry powder administration
- Drug Delivery Device Development: Industrialization-scale, comprehensive services develop and industrialize drug delivery devices, covering the full pathway from design to manufacturing for pharmaceutical applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to H&T Presspart
Acorda Therapeutics
HQ: United States
Website
- Description: Provider of commercial-stage biopharmaceutical therapies, identifying, developing and commercializing therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other nervous system disorders. Products include INBRIJA (levodopa inhalation powder for Parkinson’s symptoms), AMPYRA (dalfampridine to improve walking in adults with MS), and the ARCUS drug delivery platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acorda Therapeutics company profile →
Elektrofi
HQ: United States
Website
- Description: Provider of a microparticle platform (Hypercon) enabling low-volume, stable, hyper-concentrated biologic formulations for subcutaneous delivery, alongside formulation development services—covering process development, formulation, analytics, and innovation—and partnership programs with pharmaceutical companies to develop and commercialize subcutaneous biologic therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elektrofi company profile →
Atossa Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for breast cancer, including proprietary (Z)-endoxifen, a SERM for prevention and treatment, and clinical studies: EVANGELINE Phase 2 neoadjuvant trial in ER+/HER2- pre-menopausal women; Karisma Endoxifen Trial to reduce mammographic breast density; and I-Spy 2 evaluating endoxifen to lower recurrence risk in ER+ invasive breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atossa Therapeutics company profile →
Retractable Technologies
HQ: United States
Website
- Description: Provider of safety medical products for the healthcare profession, focused on automated needle retraction to reduce needlestick injuries. Offerings include VanishPoint syringes (including U-100 insulin), blood collection sets and tube holders, IV catheters, and EasyPoint retractable needles, with one-handed or in‑vein activation, accurate dose delivery, and reduced disposal space.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Retractable Technologies company profile →
Incline Therapeutics
HQ: United States
Website
- Description: Provider of hospital-focused specialty pharmaceutical solutions, developing IONSYS (fentanyl iontophoretic transdermal system), a pharmaceutical device for the treatment of post-operative pain in hospital settings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Incline Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for H&T Presspart
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to H&T Presspart
2.2 - Growth funds investing in similar companies to H&T Presspart
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for H&T Presspart
4.2 - Public trading comparable groups for H&T Presspart
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →